Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Status:
Completed
Trial end date:
2021-06-17
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed
after skin tape stripping (STS) in pre-defined lesional skin in patients with moderate to
severe atopic dermatitis (AD) treated with dupilumab
Secondary Objectives:
- Evaluate changes in skin barrier function with TEWL assessed after STS in pre-defined
lesional and non-lesional skin in patients with moderate to severe AD treated with
dupilumab in reference to normal skin of healthy volunteers.
- Evaluate time course of skin barrier function with TEWL assessed before and after STS in
pre-defined lesional and non-lesional skin in patients with moderate to severe AD
treated with dupilumab in reference to normal skin of healthy volunteers